The funding will accelerate commercialization of the company's first-generation Stentrode™ BCI platform, while advancing development of a frontier next-generation interface.

The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. The financing brings Synchron's total funding to $345 million.

Synchron is pioneering minimally invasive brain-computer interfaces (BCIs) to restore communication, mobility, and independence for people with paralysis. Its Stentrode™ platform is the first endovascular BCI designed to translate thought into digital action without open-brain surgery, combining neurointerventional access, device engineering, and NeuroAI to create scalable, real-world neural interfaces.